A major goal of a new multidrug platform study organized by the Pancreatic Cancer Action Network is to meet patients' needs better than traditional trials do. Among other things, that means accepting patients who have had a wide range of prior therapies and allowing them to cross over to new treatments following progression. It also means incorporating individual patient preferences into the randomization algorithms.
PanCAN believes Precision Promise will dramatically increase the proportion of pancreatic cancer patients who participate in clinical trials, which Chief Research Officer Lynn Matrisian told BioCentury has been a barrier to development of new treatments.
Only about 4% of patients participate in clinical trials, corresponding to roughly 2,000 patients in the U.S. each year. Matrisian said competition for patients means pancreatic cancer trial readouts are often delayed or never happen.
Reasons for low participation include strict enrollment criteria that limit prior therapies, distance from a participating trial site and lack of awareness of appropriate trials.
Enrollment criteria have not yet been determined. But Matrisian told BioCentury, "We are aiming to relax as many of the standard exclusion criteria as possible and have substudies for all lines of therapy."
Precision Promise should not only enable more patients to participate, but also should allow them to remain on study longer due